# Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris

> **NCT05131373** · PHASE1 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 38 (actual)

## Conditions studied

- Acne Vulgaris
- Acne

## Interventions

- **DRUG:** ORG101 - Experimental 1
- **DRUG:** ORG101PL - Placebo 1

## Key facts

- **NCT ID:** NCT05131373
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-28
- **Primary completion:** 2023-11-27
- **Final completion:** 2023-11-27
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05131373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05131373, "Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05131373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*